Idexx Laboratories, Inc.

Brion Mermer

Robert L Lawton

Hongliang Guo

Ashok P Aiyappa

Eugene Regis Krah, Iii

Randall G Groat

Thomas P O'Connor

Greg Francoeur

Wendy W Liu

Disclosed are binding proteins that specifically bind to an isolated and purified peptide comprising a leucine positioned two peptide bonds away from a tyrosine-arginine pair. Other binding proteins of the invention include those that specifically bind to an isolated and purified peptide with the sequence cysteine-blank-blank-proline-histidine-blank-blank-blank-cysteine (SEQ ID NO:6) or cysteine-blank-proline-histidine-blank-proline-blank-blank-cysteine (SEQ ID NO:9).

Specific binding proteins for treating canine allergy

The present invention provides the nucleotide and amino acid sequences of canine IL-5. It also sets forth a recombinant DNA molecule, and conservative variants thereof, comprising the DNA sequence of canine IL-5, and recombinant vectors such as expression vectors, comprising a DNA sequence encoding canine IL-5. Further, the invention sets forth polypeptides produced using a recombinant expression vector containing a canine IL-5 sequence. Also disclosed are compositions comprising a nucleotide sequence that is antisense to a DNA sequence encoding a component of canine IL-5, wherein the component can be the full canine IL-5 protein. Disclosed are a cloning vector comprising a DNA sequence of canine IL-5 cDNA material; a recombinant cell line comprising a DNA sequence of the canine IL-5 cDNA material; a method for producing a polypeptide comprising a step of expressing a peptide comprising an amino acid sequence encoded by a cloning vector comprising canine IL-5 cDNA material; and a cell that expresses a recombinant polypeptide encoded by a DNA sequence (or conservative variants thereof) that encodes canine IL-5 or components thereof. Furthermore, antibodies that bind to canine IL-5, and mimetopes of IL-5 epitopes are also disclosed.

Methods and compositions concerning canine interleukin 5

The present invention provides methods and compositions for decreasing IgE levels in dogs. The methods and compositions are useful for treating allergic symptoms in dogs. The invention may comprise chimeric canine anti-IgE monoclonal antibody compositions and methods for using the compositions in the treatment of allergy. In preferred embodiments, the compositions of the present invention may act by binding soluble IgE in plasma, or by inhibiting IgE from binding to receptors on mast cells, B cells, and basophils.

Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody

Methods for determining whether a feline is infected with feline immunodeficiency virus (&ldquo;FIV&rdquo;). The methods involve the use of an antibody-binding composition that includes two enhanced polypeptides, one containing an immunogenic fragment of the FIV gag precursor p55 and the other containing an immunogenic fragment of the FIV env precursor gp130. Also featured are devices for practicing these methods.

Growing community of inventors

Cumberland, ME, United States of America

Brion Mermer